Literature DB >> 23012401

CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated.

Jonathan B Overdevest1, Kristina H Knubel, Jason E Duex, Shibu Thomas, Matthew D Nitz, Michael A Harding, Steven C Smith, Henry F Frierson, Mark Conaway, Dan Theodorescu.   

Abstract

Overexpression of CD24, a glycosyl phosphatidylinositol-linked sialoglycoprotein, is associated with poor outcome in urothelial carcinoma and contributes to experimental tumor growth and metastasis. However, the requirement for CD24 (Cd24a in mice) in tumorigenesis and spontaneous metastasis from the orthotopic site remains uncharacterized. Using N-butyl-N-(4-hydroxybutyl) nitrosamine induction of invasive and metastatic bladder cancer, we show that Cd24a-deficient male mice developed fewer bladder tumors than C57BL/6 control male mice. Evaluating only mice with evidence of primary tumors, we observed that Cd24a-deficient male mice also had fewer metastases than wild-type counterparts. In parallel observations, stratification of patients based on CD24 immunohistochemical expression in their tumors revealed that high levels of CD24 are associated with poor prognosis in males. In female patients and mice the above observations were not present. Given the significant role of CD24 in males, we sought to assess the relationship between androgen and CD24 regulation. We discovered that androgen receptor knockdown in UM-UC-3 and TCCSUP human urothelial carcinoma cell lines resulted in suppression of CD24 expression and cell proliferation. Androgen treatment also led to increased CD24 promoter activity, dependent on the presence of androgen receptor. In vivo, androgen deprivation resulted in reduced growth and CD24 expression of UM-UC-3 xenografts, and the latter was rescued by exogenous CD24 overexpression. These findings demonstrate an important role for CD24 in urothelial tumorigenesis and metastasis in male mice and indicate that CD24 is androgen regulated, providing the foundation for urothelial bladder cancer therapy with antiandrogens.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23012401      PMCID: PMC3529071          DOI: 10.1073/pnas.1113960109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  47 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization.

Authors:  Jonathan B Overdevest; Shibu Thomas; Glen Kristiansen; Donna E Hansel; Steven C Smith; Dan Theodorescu
Journal:  Cancer Res       Date:  2011-04-11       Impact factor: 12.701

3.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

4.  Immunohistochemical biomarkers for bladder cancer prognosis.

Authors:  Kazuhito Matsushita; Eugene K Cha; Kazumasa Matsumoto; Shiro Baba; Thomas F Chromecki; Harun Fajkovic; Maxine Sun; Pierre I Karakiewicz; Douglas S Scherr; Shahrokh F Shariat
Journal:  Int J Urol       Date:  2011-07-20       Impact factor: 3.369

Review 5.  The novel oncogene CD24 and its arising role in the carcinogenesis of the GI tract: from research to therapy.

Authors:  Eyal Sagiv; Nadir Arber
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2008-02       Impact factor: 3.869

Review 6.  Quality of life aspects of bladder cancer: a review of the literature.

Authors:  M F Botteman; C L Pashos; R S Hauser; B L Laskin; A Redaelli
Journal:  Qual Life Res       Date:  2003-09       Impact factor: 4.147

Review 7.  Gender, racial and age differences in bladder cancer incidence and mortality.

Authors:  Ralph Madeb; Edward M Messing
Journal:  Urol Oncol       Date:  2004 Mar-Apr       Impact factor: 3.498

8.  CD24 overexpression in cancer development and progression: a meta-analysis.

Authors:  Ju-Han Lee; Seo-Hee Kim; Eung-Seok Lee; Young-Sik Kim
Journal:  Oncol Rep       Date:  2009-11       Impact factor: 3.906

9.  Sequential changes of mouse bladder epithelium during induction of invasive carcinomas by N-butyl-N-(4-hydroxybutyl)nitrosamine.

Authors:  M Ohtani; T Kakizoe; Y Nishio; S Sato; T Sugimura; S Fukushima; T Niijima
Journal:  Cancer Res       Date:  1986-04       Impact factor: 12.701

10.  A dinucleotide deletion in CD24 confers protection against autoimmune diseases.

Authors:  Lizhong Wang; Shili Lin; Kottil W Rammohan; Zhenqiu Liu; Jin-qing Liu; Run-hua Liu; Nikki Guinther; Judy Lima; Qunmin Zhou; Tony Wang; Xincheng Zheng; Dan J Birmingham; Brad H Rovin; Lee A Hebert; Yeeling Wu; D Joanne Lynn; Glenn Cooke; C Yung Yu; Pan Zheng; Yang Liu
Journal:  PLoS Genet       Date:  2007-02-21       Impact factor: 5.917

View more
  45 in total

1.  Silencing of CD24 Enhances the PRIMA-1-Induced Restoration of Mutant p53 in Prostate Cancer Cells.

Authors:  Wei Zhang; Bin Yi; Chao Wang; Dongquan Chen; Sejong Bae; Shi Wei; Rong-Jun Guo; Changming Lu; Lisa L H Nguyen; Wei-Hsiung Yang; James W Lillard; Xingyi Zhang; Lizhong Wang; Runhua Liu
Journal:  Clin Cancer Res       Date:  2015-12-28       Impact factor: 12.531

Review 2.  Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward.

Authors:  Andrea B Apolo; Vanessa Hoffman; Matthew G Kaag; David M Latini; Cheryl T Lee; Jonathan E Rosenberg; Margaret Knowles; Dan Theodorescu; Bogdan A Czerniak; Jason A Efstathiou; Matthew L Albert; Srikala S Sridhar; Vitaly Margulis; Surena F Matin; Matthew D Galsky; Donna Hansel; Ashish M Kamat; Thomas W Flaig; Angela B Smith; Edward Messing; Diane Zipursky Quale; Yair Lotan
Journal:  Urol Oncol       Date:  2014-07-25       Impact factor: 3.498

Review 3.  Targeted therapies in bladder cancer: an overview of in vivo research.

Authors:  Kim E M van Kessel; Tahlita C M Zuiverloon; Arnout R Alberts; Joost L Boormans; Ellen C Zwarthoff
Journal:  Nat Rev Urol       Date:  2015-09-22       Impact factor: 14.432

Review 4.  Hypoxia-Induced Phenotypes that Mediate Tumor Heterogeneity.

Authors:  Jin Qian; Erinn B Rankin
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

5.  Androgen receptor (AR) promotes male bladder cancer cell proliferation and migration via regulating CD24 and VEGF.

Authors:  Guoqing Ding; Shicheng Yu; Sheng Cheng; Gonghui Li; Yanlan Yu
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

6.  Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor.

Authors:  Jong-Wei Hsu; Iawen Hsu; Defeng Xu; Hiroshi Miyamoto; Liang Liang; Xue-Ru Wu; Chih-Rong Shyr; Chawnshang Chang
Journal:  Am J Pathol       Date:  2013-03-13       Impact factor: 4.307

7.  Bladder cancer: androgen-dependent CD24 regulates bladder cancer progression-a new role for antiandrogen therapy?

Authors:  Annette Fenner
Journal:  Nat Rev Urol       Date:  2012-10-16       Impact factor: 14.432

8.  Enzalutamide as an androgen receptor inhibitor prevents urothelial tumorigenesis.

Authors:  Takashi Kawahara; Satoshi Inoue; Eiji Kashiwagi; Jinbo Chen; Hiroki Ide; Taichi Mizushima; Yi Li; Yichun Zheng; Hiroshi Miyamoto
Journal:  Am J Cancer Res       Date:  2017-10-01       Impact factor: 6.166

9.  Compound A Inhibits Bladder Cancer Growth Predominantly via Glucocorticoid Receptor Transrepression.

Authors:  Yichun Zheng; Hitoshi Ishiguro; Hiroki Ide; Satoshi Inoue; Eiji Kashiwagi; Takashi Kawahara; Mehrsa Jalalizadeh; Leonardo O Reis; Hiroshi Miyamoto
Journal:  Mol Endocrinol       Date:  2015-08-31

10.  USP22 regulates oncogenic signaling pathways to drive lethal cancer progression.

Authors:  Randy S Schrecengost; Jeffry L Dean; Jonathan F Goodwin; Matthew J Schiewer; Mark W Urban; Timothy J Stanek; Robyn T Sussman; Jessica L Hicks; Ruth C Birbe; Rossitza A Draganova-Tacheva; Tapio Visakorpi; Angelo M DeMarzo; Steven B McMahon; Karen E Knudsen
Journal:  Cancer Res       Date:  2013-11-06       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.